Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: Results of a phase II study

1. Firvida, J.L.
2. Amenedo, M.
3. Rodríguez, R.
4. González, A.
5. Salgado, M.
6. Ramos, M.
7. Losada, G.